Logo image of FMTX

FORMA THERAPEUTICS HOLDINGS (FMTX) Stock Fundamental Analysis

NASDAQ:FMTX - Nasdaq - US34633R1041 - Common Stock - Currency: USD

20.01  +0.03 (+0.15%)

After market: 20.01 0 (0%)

Fundamental Rating

2

Overall FMTX gets a fundamental rating of 2 out of 10. We evaluated FMTX against 571 industry peers in the Biotechnology industry. The financial health of FMTX is average, but there are quite some concerns on its profitability. FMTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FMTX had negative earnings in the past year.
FMTX Yearly Net Income VS EBIT VS OCF VS FCFFMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 0 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA -40.02%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FMTX Yearly ROA, ROE, ROICFMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 20 -20

1.3 Margins

FMTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FMTX Yearly Profit, Operating, Gross MarginsFMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -10 -20 -30

More info and screens

6

2. Health

2.1 Basic Checks

FMTX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for FMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FMTX Yearly Shares OutstandingFMTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 10M 20M 30M 40M
FMTX Yearly Total Debt VS Total AssetsFMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

FMTX has an Altman-Z score of 8.17. This indicates that FMTX is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for FMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.17
ROIC/WACCN/A
WACCN/A
FMTX Yearly LT Debt VS Equity VS FCFFMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 12.74 indicates that FMTX has no problem at all paying its short term obligations.
FMTX has a Quick Ratio of 12.74. This indicates that FMTX is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 12.74
Quick Ratio 12.74
FMTX Yearly Current Assets VS Current LiabilitesFMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for FMTX have decreased strongly by -32.01% in the last year.
EPS 1Y (TTM)-32.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, FMTX will show a decrease in Earnings Per Share. The EPS will decrease by -2.50% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.37%
EPS Next 2Y-1.79%
EPS Next 3Y0.88%
EPS Next 5Y-2.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FMTX Yearly Revenue VS EstimatesFMTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
FMTX Yearly EPS VS EstimatesFMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FMTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FMTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FMTX Price Earnings VS Forward Price EarningsFMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.98
FMTX Per share dataFMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.79%
EPS Next 3Y0.88%

More info and screens

0

5. Dividend

5.1 Amount

FMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORMA THERAPEUTICS HOLDINGS

NASDAQ:FMTX (10/13/2022, 8:24:26 PM)

After market: 20.01 0 (0%)

20.01

+0.03 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2022-08-05/bmo
Earnings (Next)11-11 2022-11-11/bmo
Inst Owners0.69%
Inst Owner Change0%
Ins Owners5.32%
Ins Owner Change0%
Market Cap957.53M
Analysts75
Price Target21.01 (5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB N/A
EV/EBITDA -2.98
EPS(TTM)-4
EYN/A
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS8.66
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.74
Quick Ratio 12.74
Altman-Z 8.17
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.57%
EPS Next Y-17.37%
EPS Next 2Y-1.79%
EPS Next 3Y0.88%
EPS Next 5Y-2.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A